Article

Live Broadcast: Explore the Role of CAR T-Cell Therapy in Hematologic Malignancies

In an upcoming live broadcast, an opinion leader will explore unmet needs for patients with hematologic malignancies and discuss the crucial role of the primary oncology team in CAR T-cell therapy.

To obtain expert perspective on treatment options and best practices in patient selection and referral, watch the live broadcast on January 10, 2023. To register for the event, visit https://studio.mjhassoc.com/reach/kite-car-t-cell-therapy-and-primary-oncology.

Paid speaker presenting on behalf of Kite. This event is brought to you by Kite and is not eligible for CME credits.


© 2022 Kite Pharma, Inc. All rights reserved. US-UNBP-1546 12/2022

Related Videos
Drs Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D